Promis Neurosciences Inc. (PMN) Stock Price & Analysis
Promis Neurosciences Inc. (PMN) fell 3.45% to USD 12.6 as of September 8, 2026 at 12:53 UTC, according to Nexqual real-time market data.
PMN last closed at USD 13.05; the session ranged USD 12.56–13.46 on volume of 23,528 shares. Market capitalization is $112.99M, with a 52-week range of USD 6.27–27.4 (NCM). Source: Nexqual, September 8, 2026 at 12:53 UTC.
Key Statistics (as of September 8, 2026 at 12:53 UTC)
| Price | USD 12.6 |
|---|---|
| Change | ▼ 3.45% (down) |
| Previous Close | USD 13.05 |
| Open | USD 13.03 |
| Day Range | USD 12.56 – 13.46 |
| 52-Week Range | USD 6.27 – 27.4 |
| Volume | 23,528 shares |
| Market Cap | $112.99M |
| Exchange | NCM |
Technical Analysis (PMN)
Nexqual's technical model rates PMN "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 12:53 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.16 (neutral) |
| vs SMA50 | Below (USD 13.84) |
| MACD | -0.18 (negative) |
Analyst Ratings (PMN)
Wall Street analysts rate PMN "None" based on 7 analysts, with a mean price target of USD 43.94 (range USD 18.34–101.07), per Nexqual as of September 8, 2026 at 12:53 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 43.94 |
| High Target | USD 101.07 |
| Low Target | USD 18.34 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (PMN)
| EPS Estimate | USD -1.82 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.78 vs est -1.9 ▲ beat |
| 2025-12-31 | USD -30.05 vs est -6.71 ▼ miss |
| 2025-09-30 | USD -8.4 vs est -9.99 ▲ beat |
Source: Nexqual, September 8, 2026 at 12:53 UTC.
Financials & Fundamentals (PMN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -172.30% |
| Current Ratio | 7.86 |
| Total Cash | $53.46M |
| Total Debt | $0 |
| Free Cash Flow | $-26.84M |
Source: Nexqual, September 8, 2026 at 12:53 UTC.
Financial Health Score (PMN)
Nexqual rates Promis Neurosciences Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 12:53 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $53M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$42M |
| Efficiency | Critical — ROE -172%, ROA -81.1% |
Ownership (PMN)
| Insider Ownership | +11.87% |
|---|---|
| Institutional Ownership | +77.26% |
| Shares Outstanding | 8.97M |
| Float | 4.39M |
| Short % of Float | +3.15% |
Source: Nexqual, September 8, 2026 at 12:53 UTC.
Leadership (PMN)
Promis Neurosciences Inc. is led by Neil K. Warma (age 62), CEO, President, Compliance Officer & Director, per Nexqual as of September 8, 2026 at 12:53 UTC.
| CEO, President, Compliance Officer & Director | Neil K. Warma (age 62) |
|---|---|
| Co-Founder & Chairman | Eugene W. Williams (age 66) |
| Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director | Neil R. Cashman (age 73) |
| Chief Financial Officer | Daniel E. Geffken (age 68) |
Major Backers & Investors (PMN)
Notable institutional backers of Promis Neurosciences Inc. include Jupiter Topco LLC, Deep Track Capital, Lp, Wellington Management, according to Nexqual as of September 8, 2026 at 12:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jupiter Topco LLC | 14.42% |
| Deep Track Capital, Lp | 9.32% |
| Wellington Management | 7.77% |
| Ally Bridge Group (NY) LLC | 6.92% |
| Trails Edge Capital Partners, LP | 6.21% |
| Woodline Partners LP | 4.93% |
| Yu Fan | 3.68% |
| Sphera Funds Management Ltd. | 3.63% |
Source: Nexqual, September 8, 2026 at 12:53 UTC.
From Promis Neurosciences Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
- The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing.
- Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy.
- The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BGLC | BioNexus Gene Lab Corp | USD 1.45 | ▼ 1.36% |
| BDRX | Biodexa Pharmaceuticals plc | USD 0.85 | ▲ 8.03% |
| MLEC | Moolec Science SA | USD 6.93 | ▲ 1.76% |
| ZVSA | ZyVersa Therapeutics, Inc. | USD 0.1 | ▲ 4.04% |
| AIMD | Ainos, Inc. | USD 1.6 | ▲ 1.27% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:53 UTC. This page is informational and not investment advice.